Impulse Control Disorder Clinical Trial
Official title:
Effects of Non-invasive Brain on Decision-making in Impulse Control Disorders
Verified date | October 2017 |
Source | Laval University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this project is to study the effect of noninvasive brain stimulation on decision-making and on brain activity in impulse control disorders.
Status | Active, not recruiting |
Enrollment | 18 |
Est. completion date | January 2018 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Impulse control disorders according to DSM-IV criteria Exclusion Criteria: - Other psychiatric disorders - Contraindication to Non-invasive brain stimulation and MRI |
Country | Name | City | State |
---|---|---|---|
Canada | Centre Interdisciplinaire de Recherche en Réadaptation et Intégration | Québec | Quebec |
Lead Sponsor | Collaborator |
---|---|
Laval University |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in decision-making from pre to post stimulation assessed with the Balloon Analogue Risk Task | 10 minutes before and immediately after the 30 minutes of non invasive brain stimulation | ||
Secondary | Changes in brain activity assessed between before and during stimulation measured with functional magnetic resonance (fMRI) | 20 minutes before and immediately after the 30 minutes of non invasive brain stimulation | ||
Secondary | Neural metabolites concentrations measured with magnetic resonance spectroscopy (MRS) | 20 minutes before and immediately after the 30 minutes of non invasive brain stimulation | ||
Secondary | Change in Craving from pre to post stimulation assessed with a single standardized scale | 7 minutes before and 3 minutes after the end of the 30 minutes of non invasive brain stimulation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01683253 -
Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa
|
Phase 4 | |
Completed |
NCT01052831 -
Naltrexone for Impulse Control Disorders in Parkinson's Disease
|
Phase 4 | |
Recruiting |
NCT06237868 -
rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease
|
N/A | |
Recruiting |
NCT05712057 -
Neurostimulation Versus Therapy for Problems With Emotions
|
N/A | |
Recruiting |
NCT03146130 -
Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders
|
Phase 3 |